Koo your statement of mining for plaque regression and finding MACE instead is not accurate. RVX did find plaque regression in a big way in the RVX-208 + rosuvastatin cohort of the trial. One of the reasons I have hope that at the very least this cohort will show success with a big reduction in RRR of MACE is that if the plaque reduction is occurring over the long term in a similar way as it did in the shorter trial then the CV disease burden in these patients is very likely being reduced.

In retrospect IMO one of the biggest mistakes RVX management has ever made was, in ASSURE, not making the differentiation between rosuvastatin + 208 and atorvastatin + 208 a prespecified end point. To me heads should have rolled after that one.